Table 5. Clinical trials evaluating antigen-naïve DCs, DC-derived exosomes and in vivo DC targeting as immunotherapeutic interventions for cancer therapy.*.

Approach	Indications	Trials	Phase	Status	Notes	Ref.
Allogeneic DCs	Renal cell carcinoma	1	I	Recruiting	As single agent	NCT01525017
Autologous DCs	AML	2	I	Completed	As single agent	NCT00963521
			I	Recruiting	Irradiated DCs, as a single agent	NCT01373515
	HNC	1	I	Unknown	iDCs, combined with cyclophosphamide, docetaxel and picibanil	NCT01149902
	Multiple myeloma	1	I-II	Unknown	Combined with lenalidomide	NCT00698776
	Pancreatic cancer	1	I-II	Active, not recruiting	iDCs, alone or combined with picibanil	NCT00795977
	Prostate cancer	2	I-II	Active, not recruiting	iDCs, as single agent	NCT00753220
			II	Suspended	Combined with allogeneic tumor-cell vaccine	NCT00814892
	Soft tissue sarcoma	1	II	Recruiting	Combined with radiotherapy	NCT01347034
DC-derived exosomes	NSCLC	1	II	Recruiting	As a single agent	NCT01159288
Genetically engineered autologous DCs	Melanoma	1	I	Active, not recruiting	IL-12-expressing DCs, as single agent	NCT00815607
	NSCLC	2	I	Recruiting	CCL21-expressing DCs, as single agent	NCT00601094
						NCT01574222
In vivo DC targeting	NY-ESO-1-expressing solid tumors	1	I	Recruiting	Alone or combined with sirolimus	NCT01522820

AML, acute myeloid leukemia; DC, dendritic cell; HNC, head and neck cancer; iDC, immature DC; IL-12, interleukin-12; mDC, mature DC; NSCLC, non-small cell lung carcinoma. *Started after January, 1st 2008.